Study guide
5.4 Traumatic Brain Injury & Spinal Cord Emergencies
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
5.4 Traumatic Brain Injury & Spinal Cord Emergencies
Key Takeaways Explain This Topic AI
Brain Trauma Foundation (BTF) guidelines mandate avoiding secondary insults in severe TBI (GCS <=8), maintaining SBP >=100 mmHg (age 50–69) or >=110 mmHg (age 15–49 or >=70), PaO2 >=60 mmHg, and targeting CPP 60 to 70 mmHg.
Prophylactic hyperventilation (PaCO2 <35 mmHg) is contraindicated in the acute phase of severe TBI because cerebral vasoconstriction induces profound secondary ischemia; normocarbia (PaCO2 35–45 mmHg) is standard.
Post-traumatic seizure (PTS) prophylaxis with levetiracetam (1000 mg IV q12h) or phenytoin (load 15–20 mg/kg, target 10–20 mcg/mL) is used for the first 7 days after severe TBI; therapy beyond 7 days confers no benefit in preventing post-traumatic epilepsy.
In acute spinal cord injury, high-dose methylprednisolone is not standard care; neurogenic shock is treated with norepinephrine (or epinephrine) to a MAP of 85–90 mmHg for 7 days (AANS/CNS 2013) or at least 75–80 mmHg for 3–7 days under the 2024 AO Spine/Praxis guideline.
Last updated: October 2026
5.4 Traumatic Brain Injury & Spinal Cord Emergencies
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around neurocritical care and emergency pharmacotherapy principles.
Neurotrauma represents a major source of critical morbidity and mortality encountered in the emergency department. Traumatic neurovascular injuries require rapid physiological resuscitation centered on preventing secondary cellular damage. In severe traumatic brain injury (TBI) and acute spinal cord injury (SCI), the primary mechanical insult (contusion, hemorrhage, parenchymal laceration) occurs instantaneously at the moment of impact and cannot be reversed pharmacologically. Clinical emergency medicine pharmacotherapy focuses entirely on mitigating secondary insults —including systemic hypotension, arterial hypoxemia, cerebral hypoperfusion, intracranial hypertension, and post-traumatic seizures.
Severe Traumatic Brain Injury (TBI, GCS ≤ 8 \le 8 ≤ 8 ): Secondary Insult Mitigation
The Brain Trauma Foundation (BTF) Guidelines (4th Edition) establish evidence-based parameters designed to protect the vulnerable, ischemic penumbra following severe head injury:
1. Hemodynamic Targets: Blood Pressure & Hypoxia
Secondary physiological insults dramatically escalate mortality in severe TBI:
Hypotension : Even a single documented episode of systemic systolic blood pressure < 90 mmHg <90\text{ mmHg} < 90 mmHg doubles mortality in severe TBI. Current BTF guidelines define specific, age-adjusted systolic thresholds:
Age 50 to 69 years : Maintain SBP ≥ 100 mmHg \ge 100\text{ mmHg} ≥ 100 mmHg .
Age 15 to 49 years OR ≥ 70 \ge 70 ≥ 70 years : Maintain SBP ≥ 110 mmHg \ge 110\text{ mmHg} ≥ 110 mmHg .
Hypoxia : Maintain P a O 2 ≥ 60 mmHg PaO_2 \ge 60\text{ mmHg} P a O 2 ≥ 60 mmHg or S p O 2 ≥ 90 % SpO_2 \ge 90\% Sp O 2 ≥ 90% . Avoid hyperoxia ( P a O 2 > 300 mmHg PaO_2 >300\text{ mmHg} P a O 2 > 300 mmHg ), which triggers reactive oxygen species production and cerebral vasoconstriction.
The Lethal Combination : The co-occurrence of both systemic hypotension and arterial hypoxia quadruples mortality in severe neurotrauma patients.
2. Cerebral Perfusion Pressure (CPP) & Intracranial Pressure (ICP)
Cerebral perfusion pressure represents the net pressure gradient driving oxygenated blood delivery across cerebral vascular beds:
C P P = M A P − I C P CPP = MAP - ICP CPP = M A P − I CP
Target CPP Threshold : Maintain CPP between 60 and 70 mmHg .
Avoid CPP < 60 mmHg <60\text{ mmHg} < 60 mmHg : Insufficient perfusion triggers severe microvascular cerebral ischemia and accelerates infarction of the contused penumbra.
Avoid CPP > 70 mmHg >70\text{ mmHg} > 70 mmHg : Aggressive fluid loading and high-dose vasopressor titration to push CPP above 70 mmHg significantly elevates pulmonary capillary hydrostatic pressure, increasing the incidence of acute respiratory distress syndrome (ARDS) and acute lung injury five-fold without conferring any neurological benefit.
ICP Monitoring Indications : An indwelling intracranial pressure monitor (external ventricular drain [EVD] or intraparenchymal fiberoptic probe) is indicated in all salvageable severe TBI patients (GCS 3 to 8 after cardiopulmonary resuscitation) who exhibit an abnormal admission head CT (hematoma, contusions, swelling, compressed basal cisterns). It is also indicated in severe TBI patients with a normal head CT if two or more of the following criteria are met upon admission: age > 40 >40 > 40 years, unilateral or bilateral motor posturing, or SBP < 90 mmHg <90\text{ mmHg} < 90 mmHg .
ICP Treatment Threshold : Initiate active osmotherapy and neurocritical interventions when sustained ICP exceeds 22 mmHg 22\text{ mmHg} 22 mmHg .
3. Ventilation Management & The Dangers of Hyperventilation
Cerebral arterioles are exquisitely sensitive to alterations in arterial carbon dioxide tension ( P a C O 2 PaCO_2 P a C O 2 ):
Normocarbia Standard : Maintain arterial P a C O 2 PaCO_2 P a C O 2 between 35 and 45 mmHg .
The Danger of Hyperventilation : Prophylactic hyperventilation ( P a C O 2 < 35 mmHg PaCO_2 <35\text{ mmHg} P a C O 2 < 35 mmHg ) is strongly contraindicated during the first 24 to 48 hours post-injury. Hypocapnia induces severe cerebral vasoconstriction, drastically reducing cerebral blood flow ( C B F CBF CBF ) at a time when cerebral perfusion is already reduced by 50% compared to baseline, causing profound secondary ischemic infarction.
The Sole Exception : Brief, mild hyperventilation ( P a C O 2 30 to 35 mmHg PaCO_2\text{ 30 to 35 mmHg} P a C O 2 30 to 35 mmHg ) is reserved exclusively as a temporary rescue temporizing maneuver during acute, life-threatening uncal herniation (pupillary asymmetry, extensor posturing, sudden GCS drop) while hypertonic saline or mannitol is rapidly infused.
Post-Traumatic Seizure (PTS) Prophylaxis: The 7-Day Rule
Post-traumatic seizures are categorized temporally into early PTS (occurring within 7 days of injury) and late PTS (occurring > 7 >7 > 7 days post-injury, representing true post-traumatic epilepsy). Early seizures occur in 4% to 25% of severe TBI patients and drastically increase cerebral metabolic oxygen consumption ( C M R O 2 CMRO_2 CMR O 2 ), intracranial pressure, and secondary brain injury.
Loading diagram...
Clinical Practice Guidelines for PTS Prophylaxis
Guideline Recommendation : Antiseizure prophylaxis is recommended to decrease the incidence of early post-traumatic seizures for the first 7 days post-injury in high-risk patients (GCS ≤ 8 \le 8 ≤ 8 , cortical contusions, depressed skull fracture, subdural/epidural/intracerebral hematoma, penetrating brain injury, or acute seizure at presentation).
The 7-Day Limit : Prophylactic antiseizure medication beyond 7 days is not recommended . Large randomized controlled trials have demonstrated that continuing anticonvulsants beyond 7 days does NOT decrease the incidence of late post-traumatic epilepsy or improve long-term functional recovery, while exposing patients to adverse drug reactions, hepatic toxicity, and drug interactions.
Pharmacotherapeutic Options: Levetiracetam vs. Phenytoin
Levetiracetam (Keppra) :
Dosing : 1000 mg IV every 12 hours (some centers initiate with a loading dose of 20 to 30 mg/kg IV).
Clinical Pearls : Preferred in clinical neurotrauma practice over phenytoin due to lack of therapeutic drug monitoring, absence of hepatic cytochrome P450 enzyme induction, fewer adverse drug events, and zero risk of cardiac dysrhythmias or purple glove syndrome. Requires dosage adjustment in renal impairment.
Phenytoin / Fosphenytoin :
Dosing : Loading dose of 15 to 20 mg/kg IV (or fosphenytoin 15 to 20 mg PE/kg IV); maintenance dose 100 mg IV/PO every 8 hours (4 to 6 mg/kg/day).
Therapeutic Target : Total serum phenytoin level 10 to 20 mcg/mL (free phenytoin level 1 to 2 mcg/mL ).
Winter's-Tozer Albumin Correction : In trauma and critical illness, hypoalbuminemia causes total phenytoin levels to appear falsely depressed due to decreased plasma protein binding, while the pharmacologically active unbound (free) fraction remains normal or elevated. Adjust total concentration using the Winter's-Tozer equation:
P h e n y t o i n a d j u s t e d = P h e n y t o i n m e a s u r e d ( 0.2 × Serum Albumin [g/dL] ) + 0.1 Phenytoin_{adjusted} = \frac{Phenytoin_{measured}}{(0.2 \times \text{Serum Albumin [g/dL]}) + 0.1} P h e n y t o i n a d j u s t e d = ( 0.2 × Serum Albumin [g/dL] ) + 0.1 P h e n y t o i n m e a s u re d
Acute Spinal Cord Injury (SCI): Deconstructing the NASCIS Steroid Paradigm
For decades, high-dose methylprednisolone was routinely administered in acute traumatic spinal cord injury based on the National Acute Spinal Cord Injury Studies (NASCIS II and III) protocols (30 mg/kg IV bolus over 15 minutes, followed 45 minutes later by a continuous infusion of 5.4 mg/kg/h for 23 to 47 hours).
Contemporary Guideline Consensus (AANS / CNS Guidelines)
Recommendation : The 2013 AANS/CNS guideline does not recommend high-dose methylprednisolone for acute spinal cord injury. The 2017 AO Spine guideline is more permissive, suggesting that a 24-hour infusion started within 8 hours of injury may be offered to selected adults, so practice varies; prolonged 48-hour courses are not supported.
Evidence Summary : Rigorous re-analysis of the NASCIS trials and multiple subsequent systematic reviews demonstrated that high-dose corticosteroids provide no consistent, clinically meaningful improvement in long-term neurological or functional recovery . Conversely, high-dose corticosteroid infusions produce a statistically significant increase in severe, life-threatening complications, including severe pneumonia, hospital-acquired infections, bacteremia/sepsis, gastrointestinal ulceration/hemorrhage, acute myopathy, and overall mortality.
Neurogenic Shock vs. Spinal Shock: Critical Hemodynamic Differentiation
Emergency clinicians frequently confuse neurogenic shock and spinal shock, yet their underlying pathophysiology and therapeutic management differ fundamentally.
1. Neurogenic Shock
Pathophysiology : A severe form of distributive shock resulting from the disruption of descending sympathetic autonomic pathways in cervical and high thoracic spinal cord injuries (typically at or above T6 ).
Mechanistic Profile :
Loss of Sympathetic Vasomotor Tone : Severe, unopposed arteriolar and venous dilation causes massive pooling of blood in peripheral capacitive beds → \rightarrow → profound systemic hypotension .
Loss of Cardiac Accelerator Fibers (T1 to T4) : Leaves cardiac sinoatrial and atrioventricular nodal pacing under unopposed parasympathetic (vagal) tone → \rightarrow → relative or absolute bradycardia .
Poikilothermia / Hypothermia : Vasodilation causes heat loss; extremities are initially warm, dry, and well-perfused (unlike the cold, clammy extremities seen in hemorrhagic or cardiogenic shock).
The Classic Triad : Hypotension, bradycardia, and hypothermia / poikilothermia .
2. Spinal Shock
Pathophysiology : A transient, localized neurophysiologic phenomenon characterized by the complete temporary loss or depression of all sensorimotor and spinal reflex activity below the level of the injury.
Clinical Presentation : Flaccid muscle paralysis, absent deep tendon reflexes, loss of bowel and bladder sphincter tone, and loss of the bulbocavernosus reflex. It is not a hemodynamic state of circulatory failure .
Resolution : Reflex activity gradually returns over days to weeks, typically transitioning into long-term spasticity and hyperreflexia.
Perfusion Targets & Vasopressor Management in Acute SCI
Because the injured spinal cord exhibits disrupted local microvascular autoregulation, spinal cord blood flow becomes directly dependent on systemic perfusion pressure. Systemic hypotension worsens secondary cord ischemia, converting an incomplete spinal injury into a permanent complete deficit.
Perfusion Target
Guideline Goal : The 2013 AANS/CNS guideline suggests a Mean Arterial Pressure (MAP) of 85 to 90 mmHg for the first 7 days after injury. The 2024 AO Spine/Praxis hemodynamic guideline is less aggressive, suggesting a MAP of at least 75 to 80 mmHg as the lower limit and no more than 90 to 95 mmHg as the upper limit, for 3 to 7 days . Know both; many centers now use the newer range.
Vasopressor Selection Architecture
Because neurogenic shock produces both profound vasodilation and bradycardia, optimal vasopressor pharmacotherapy requires agents that provide both alpha-1 (vasoconstriction) and beta-1 (inotropy/chronotropy) adrenergic receptor stimulation:
Norepinephrine (First-Line) :
Receptor Profile : Potent alpha-1 agonist with moderate beta-1 adrenergic activity.
Clinical Rationale : Effectively restores systemic vascular resistance while beta-1 activity supports heart rate and cardiac output against unopposed vagal tone. Drug of choice for cervical and high-thoracic neurogenic shock.
Epinephrine (Alternative First-Line) :
Receptor Profile : Potent non-selective alpha and beta agonist.
Clinical Rationale : Excellent alternative, particularly when severe, symptomatic bradycardia predominates and does not respond adequately to norepinephrine.
Phenylephrine Warning :
Receptor Profile : Pure, selective alpha-1 adrenergic agonist without beta activity.
Critical Hazard : Increases systemic vascular resistance, but the resulting afterload spike stimulates carotid baroreceptors, triggering reflex bradycardia . In a patient who has already lost cardiac sympathetic tone, phenylephrine can precipitate catastrophic bradyasystole and cardiovascular collapse. Avoid in cervical and high-thoracic SCI (may be considered only for low-thoracic or lumbar injuries where cardiac sympathetic innervation [T1-T4] is intact).
Dopamine Limitations :
While historically used, dopamine is associated with significantly higher rates of tachyarrhythmias, excessive tachycardia, and failure to consistently achieve MAP targets compared to norepinephrine.
Neurotrauma Resuscitation Reference Matrix
Clinical Condition Primary Hemodynamic Target First-Line Pharmacotherapy Critical Duration / Monitoring Prohibited / Ineffective Interventions
Severe TBI (GCS ≤ 8 \le 8 ≤ 8 ) SBP ≥ 100 \ge 100 ≥ 100 (age 50–69) or ≥ 110 \ge 110 ≥ 110 (15–49, ≥ 70 \ge 70 ≥ 70 ); CPP 60–70 mmHg IV Norepinephrine (support MAP); 3% NaCl or Mannitol (ICP >22) Continuous arterial line and ICP monitoring Avoid CPP >70 mmHg (ARDS risk). Avoid prophylactic hyperventilation ( P a C O 2 < 35 PaCO_2 <35 P a C O 2 < 35 ).
TBI Seizure Prophylaxis Prevent early post-traumatic seizures (0–7 days) Levetiracetam 1000 mg IV q12h OR Phenytoin 15–20 mg/kg load 7 days of therapy , then discontinue Prophylaxis beyond 7 days is ineffective for preventing late epilepsy; do not continue.
Acute Spinal Cord Injury MAP 85 to 90 mmHg Norepinephrine IV infusion (balanced alpha-1 and beta-1) Maintain MAP target for 7 days post-injury High-dose methylprednisolone (NASCIS) is not recommended (infection/death risk).
Neurogenic Shock Restore SVR and HR (triad: hypotension, bradycardia, poikilothermia) Norepinephrine or Epinephrine continuous infusion Maintain MAP 85–90 mmHg; pacing/atropine for refractory bradycardia Avoid Phenylephrine (triggers reflex bradycardia in cervical/high-thoracic lesions).